02:36 , Aug 24, 2018 |  BC Innovations  |  Targets & Mechanisms

Computing checkpoints

After 25 years as a discovery company, Compugen Ltd. is about to enter the clinic for the first time with a first-in-class mAb against a new checkpoint target. The target’s expression on adaptive immune cells,...
08:00 , Jan 29, 2015 |  BC Innovations  |  Targets & Mechanisms

Going TIGITal

Among the host of new targets being explored for combination with anti- PD-1 therapies, TIGIT stands out for its unique mechanism that complements PD-1's control of T cell activation. Preclinical results from the Genentech Inc....
08:00 , Jan 22, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: T-cell immunoreceptor with Ig and ITIM domains (TIGIT)

Cancer INDICATION: Cancer Studies in human tissue samples and mice suggest combined blockade of the PD-L1 and TIGIT coinhibitory receptors could help treat cancer. In human tumor samples, TIGIT was up-regulated in tumor-infiltrating CD8+ T...
07:00 , Oct 28, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Transplantation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Transplantation Graft-versus-host disease (GvHD) CD226 (DNAM-1) Mouse studies suggest that inhibiting DNAM-1 could help treat GvHD. In irradiated mice receiving a bone marrow transplant, an anti-DNAM-1...
08:00 , Jan 22, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Multiple myeloma (MM) CD226 (DNAM-1); killer cell lectin-like receptor subfamily K, member 1 (KLRK1; NKG2D) A study in patient samples and...